PFA
PCRX icon

Pathway Financial Advisers’s Pacira BioSciences PCRX Stock Holding History

Pathway Financial Advisers’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-28
Closed -$945 – 486
2023
Q4 		$945 Hold
28
– – ﹤0.01% 456
2023
Q3 		$859 Buy
+28
New +$1.01K ﹤0.01% 467
2023
Q1 		$2.87K Sell
70
-334
-83% -$13.3K ﹤0.01% 467
2022
Q4 		$15.6K Buy
+404
New +$19.7K 0.01% 357

Other funds holding PCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Pathway Financial Advisers's PCRX Position: Q1 2024 in Review

Pathway Financial Advisers sold out of Pacira BioSciences (PCRX) in Q1 2024, closing a stake of 28 shares — an estimated $945 sold.

Pathway Financial Advisers first reported a position in PCRX in Q4 2022 and held it in 4 quarters. The position peaked at $15.6K in Q4 2022. 270 funds tracked by Wall St. Rank hold PCRX as of Q1 2024.

  • Pathway Financial Advisers reported no remaining Pacira BioSciences position as of Q1 2024 after selling out during the quarter.
  • Pathway Financial Advisers sold 28 Pacira BioSciences shares in Q1 2024, an estimated $945.
  • Pathway Financial Advisers first reported a position in Pacira BioSciences in Q4 2022 and held it in 4 quarters.
  • Pathway Financial Advisers's Pacira BioSciences position peaked at $15.6K in Q4 2022.
  • 270 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2024.

Based on Pathway Financial Advisers's 13F filing for Q1 2024, filed 29 May 2024.